Literature DB >> 20234320

Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.

Katsuhiko Shimizu1, Masao Nakata, Yuji Hirami, Takuro Yukawa, Ai Maeda, Kazuo Tanemoto.   

Abstract

BACKGROUND: Cyclooxygenase-2 (COX-2) is constitutively overexpressed in a variety of epithelial malignancies and is usually associated with a poor prognosis. COX-2-derived prostaglandin E2 transforms CD4+CD25+ T regulatory (Treg) cells (Tregs), and Tregs are thought to moderate the antitumor immune response. Herein, we investigated the prognostic value of tumor-infiltrating Treg cells and their correlation with COX-2 expression in resected non-small cell lung cancer (NSCLC).
MATERIAL AND METHODS: Intratumoral COX-2 and Treg expression were retrospectively assessed using immunohistochemistry in paraffin-embedded samples from 100 patients who had undergone complete resections for NSCLC. The expressions of COX-2 and Foxp3, which was most specific Treg cell marker, were compared with the clinicopathological variables, and the correlation between Foxp3+ Tregs and COX-2 expression was analyzed.
RESULTS: The recurrence-free survival (RFS) of patients with elevated COX-2 expression was significantly worse than that of patients without COX-2 expression. Tumor-infiltrating Foxp3-positive lymphocytes were positively correlated with COX-2 expression. The median count for Foxp3-positive lymphocytes was 3 (minimum-maximum, 0-24) in 10 high-power fields. The RFS of patients with tumors containing >or=3 Foxp3-positive cells (Foxp3 expression group) was significantly worse than that of patients with tumors containing <3 Foxp3-positive cells. In a multivariate analysis, only nodal status was an independent predictor of a significantly shorter RFS. However, in node-negative NSCLC, Foxp3 expression was an independent predictor of a significantly shorter RFS.
CONCLUSIONS: Tumor-infiltrating Foxp3+ Tregs were positively correlated with intratumoral COX-2 expression and were associated with a worse RFS, especially among patients with node-negative NSCLC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20234320     DOI: 10.1097/JTO.0b013e3181d60fd7

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  102 in total

Review 1.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

2.  In reply: Tumor-associated lymphocytes expanded ex vivo from malignant ascites.

Authors:  Shin Wha Lee; Yong-Man Kim
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

3.  Increased expression of CD4+CD25 +FOXP3+ regulatory T cells correlates with Epstein-Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil.

Authors:  Mariane C G Assis; Antonio H F M Campos; Jose S R Oliveira; Fernando A Soares; Joyce M K Silva; Priscilla B Silva; Adriana D Penna; Eni M Souza; Otavio C G Baiocchi
Journal:  Med Oncol       Date:  2012-07-13       Impact factor: 3.064

4.  Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung.

Authors:  Akiko Takahashi; Genichiro Ishii; Tomonari Kinoshita; Tatsuya Yoshida; Shigeki Umemura; Tomoyuki Hishida; Kiyotaka Yoh; Seiji Niho; Koichi Goto; Hironobu Ohmatsu; Yuichiro Ohe; Kanji Nagai; Atsushi Ochiai
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-07       Impact factor: 4.553

Review 5.  Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas.

Authors:  Shisuo Du; Mary Helen Barcellos-Hoff
Journal:  Semin Radiat Oncol       Date:  2013-10       Impact factor: 5.934

Review 6.  Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.

Authors:  Mauricio Burotto; Anish Thomas; Deepa Subramaniam; Giuseppe Giaccone; Arun Rajan
Journal:  J Thorac Oncol       Date:  2014-11       Impact factor: 15.609

7.  Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter.

Authors:  Kobe Reynders; Dirk De Ruysscher
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

8.  Urinary levels of prostaglandin E2 are positively correlated with intratumoral infiltration of Foxp3+ regulatory T cells in non-small cell lung cancer.

Authors:  Katsuhiko Shimizu; Riki Okita; Shinsuke Saisho; Ai Maeda; Yuji Nojima; Masao Nakata
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

9.  Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer.

Authors:  Candice C Black; Mary Jo Turk; Konstantin Dragnev; James R Rigas
Journal:  Lung       Date:  2013-03-15       Impact factor: 2.584

10.  Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma.

Authors:  Lei Zhao; Jin Yang; Hui-Ping Wang; Rong-Yu Liu
Journal:  Med Oncol       Date:  2013-01-20       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.